Hemab
Signal active
Organization
Contact Information
Overview
Hemab is a company that creates preventative treatments for bleeding and thrombosis problems. The medicines developed by the business aggregate, modify, balance, and at times recruit endogenous clotting components already present in the blood to the site of injury, allowing patients to produce hemostatic plugs or clots to avert life-threatening complications.
Hemab Therapeutics was established in 2017 in Copenhagen, Hovedstaden by Johan H. Faber and Mads Behrndt.
About
Industries
Biotechnology, Life Science, Pharmaceutical
Founded
2017
Employees
11-50
Headquarters locations
Europe
Social
N/A
Profile Resume
Hemab headquartered in Europe, operates in the Biotechnology, Life Science, Pharmaceutical sector. The company focuses on Biotechnology and has secured $6.8B in funding across 36 round(s). With a team of 11-50 employees, Hemab is actively contributing to advancements in Biotechnology. Their latest funding round, Series B - Hemab, raised $135.0M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
Funding rounds
3
Investors
9
Lead Investors
0
Total Funding Amount
$190.0M
Details
3
Hemab has raised a total of $190.0M in funding over 3 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2020 | Seed | |||
| 2021 | Early Stage Venture | 55.0M | ||
| 2023 | Early Stage Venture | 135.0M |
Investors
Hemab is funded by 22 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| Christine Borowski | - | FUNDING ROUND - Christine Borowski | 135.0M |
| Dan Becker | - | FUNDING ROUND - Dan Becker | 135.0M |
| Hemab | - | FUNDING ROUND - Hemab | 135.0M |
| Access Biotechnology | - | FUNDING ROUND - Access Biotechnology | 135.0M |
Recent Activity
There is no recent news or activity for this profile.